APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs based on Genetic Engineering

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs based on Genetic Engineering Market Outlook and Growth Opportunities 2026

23 December 2025201 pages

Choose your research edition.

Industry ResearchDrugs based on Genetic Engineering Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs based on Genetic Engineering Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Drugs based on Genetic Engineering Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs based on Genetic Engineering Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs based on Genetic Engineering Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Drugs based on Genetic Engineering market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs based on Genetic Engineering is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs based on Genetic Engineering is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs based on Genetic Engineering is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs based on Genetic Engineering market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs based on Genetic Engineering market include GenSci, Takeda, CSPC, 3SBIO, Sandoz, Sanofi, Johnson & Johnson, Novo Nordisk and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drugs based on Genetic Engineering market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs based on Genetic Engineering and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs based on Genetic Engineering revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs based on Genetic Engineering market.

Drugs based on Genetic Engineering Segment by Company

GenSci

Takeda

CSPC

3SBIO

Sandoz

Sanofi

Johnson & Johnson

Novo Nordisk

Merck

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Bayer

Bristol-Myers Squibb

Amgen

AbbVie

Swedish Orphan Biovitrum

Organon Pharma

Drugs based on Genetic Engineering Segment by Type

Recombinant Growth Factor

Recombinant Coagulation Factor

Recombinant Hormone

Recombinant Interferon

Recombinant Interleukin

Fusion Protein

Other

Drugs based on Genetic Engineering Segment by Application

Autoimmune Diseases

Cancers

Metabolic Disorders

Infectious Diseases

Drugs based on Genetic Engineering Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs based on Genetic Engineering status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs based on Genetic Engineering key companies, revenue, market share, and recent developments.

3. To split the Drugs based on Genetic Engineering breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs based on Genetic Engineering market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs based on Genetic Engineering significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs based on Genetic Engineering competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs based on Genetic Engineering market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs based on Genetic Engineering and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs based on Genetic Engineering.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs based on Genetic Engineering industry.

Chapter 3: Detailed analysis of Drugs based on Genetic Engineering company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs based on Genetic Engineering in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs based on Genetic Engineering in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs based on Genetic Engineering Industry Trends Table 2. Drugs based on Genetic Engineering Industry Drivers Table 3. Drugs based on Genetic Engineering Industry Opportunities and Challenges Table 4. Drugs based on Genetic Engineering Industry Restraints Table 5. Global Drugs based on Genetic Engineering Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs based on Genetic Engineering Revenue Share by Company (2021-2026) Table 7. Global Drugs based on Genetic Engineering Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs based on Genetic Engineering Key Company Manufacturing Base & Headquarters Table 9. Global Drugs based on Genetic Engineering Company, Product Type & Application Table 10. Global Drugs based on Genetic Engineering Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs based on Genetic Engineering by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Recombinant Growth Factor Table 15. Significant Companies of Recombinant Coagulation Factor Table 16. Significant Companies of Recombinant Hormone Table 17. Significant Companies of Recombinant Interferon Table 18. Significant Companies of Recombinant Interleukin Table 19. Significant Companies of Fusion Protein Table 20. Significant Companies of Other Table 21. Global Drugs based on Genetic Engineering Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Drugs based on Genetic Engineering Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Drugs based on Genetic Engineering Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Drugs based on Genetic Engineering Sales Value Share by Type (2021-2026) Table 25. Global Drugs based on Genetic Engineering Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Autoimmune Diseases Table 27. Significant Companies of Cancers Table 28. Significant Companies of Metabolic Disorders Table 29. Significant Companies of Infectious Diseases Table 30. Global Drugs based on Genetic Engineering Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs based on Genetic Engineering Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Drugs based on Genetic Engineering Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Drugs based on Genetic Engineering Sales Value Share by Application (2021-2026) Table 34. Global Drugs based on Genetic Engineering Sales Value Share by Application (2027-2032) Table 35. Global Drugs based on Genetic Engineering Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drugs based on Genetic Engineering Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Drugs based on Genetic Engineering Sales Value Share by Region (2021-2026) Table 38. Global Drugs based on Genetic Engineering Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Drugs based on Genetic Engineering Sales Value Share by Region (2027-2032) Table 40. Global Drugs based on Genetic Engineering Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Drugs based on Genetic Engineering Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Drugs based on Genetic Engineering Sales Value Market Share by Country (2021-2026) Table 43. Global Drugs based on Genetic Engineering Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Drugs based on Genetic Engineering Sales Value Market Share by Country (2027-2032) Table 45. GenSci Company Information Table 46. GenSci Business Overview Table 47. GenSci Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. GenSci Drugs based on Genetic Engineering Product Portfolio Table 49. GenSci Recent Development Table 50. Takeda Company Information Table 51. Takeda Business Overview Table 52. Takeda Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Takeda Drugs based on Genetic Engineering Product Portfolio Table 54. Takeda Recent Development Table 55. CSPC Company Information Table 56. CSPC Business Overview Table 57. CSPC Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. CSPC Drugs based on Genetic Engineering Product Portfolio Table 59. CSPC Recent Development Table 60. 3SBIO Company Information Table 61. 3SBIO Business Overview Table 62. 3SBIO Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. 3SBIO Drugs based on Genetic Engineering Product Portfolio Table 64. 3SBIO Recent Development Table 65. Sandoz Company Information Table 66. Sandoz Business Overview Table 67. Sandoz Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sandoz Drugs based on Genetic Engineering Product Portfolio Table 69. Sandoz Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Drugs based on Genetic Engineering Product Portfolio Table 74. Sanofi Recent Development Table 75. Johnson & Johnson Company Information Table 76. Johnson & Johnson Business Overview Table 77. Johnson & Johnson Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Johnson & Johnson Drugs based on Genetic Engineering Product Portfolio Table 79. Johnson & Johnson Recent Development Table 80. Novo Nordisk Company Information Table 81. Novo Nordisk Business Overview Table 82. Novo Nordisk Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Novo Nordisk Drugs based on Genetic Engineering Product Portfolio Table 84. Novo Nordisk Recent Development Table 85. Merck Company Information Table 86. Merck Business Overview Table 87. Merck Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Merck Drugs based on Genetic Engineering Product Portfolio Table 89. Merck Recent Development Table 90. Roche Company Information Table 91. Roche Business Overview Table 92. Roche Drugs based on Genetic Engineering Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Roche Drugs based on Genetic Engineering Product Portfolio Table 94. Roche Recent Development Table 95. Eli Lilly Company Information Table 96. Eli Lilly Business Overview Table 97. Eli Lilly Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Eli Lilly Drugs based on Genetic Engineering Product Portfolio Table 99. Eli Lilly Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Pfizer Drugs based on Genetic Engineering Product Portfolio Table 104. Pfizer Recent Development Table 105. GlaxoSmithKline Company Information Table 106. GlaxoSmithKline Business Overview Table 107. GlaxoSmithKline Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. GlaxoSmithKline Drugs based on Genetic Engineering Product Portfolio Table 109. GlaxoSmithKline Recent Development Table 110. Biogen Company Information Table 111. Biogen Business Overview Table 112. Biogen Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Biogen Drugs based on Genetic Engineering Product Portfolio Table 114. Biogen Recent Development Table 115. Bayer Company Information Table 116. Bayer Business Overview Table 117. Bayer Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Bayer Drugs based on Genetic Engineering Product Portfolio Table 119. Bayer Recent Development Table 120. Bristol-Myers Squibb Company Information Table 121. Bristol-Myers Squibb Business Overview Table 122. Bristol-Myers Squibb Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Bristol-Myers Squibb Drugs based on Genetic Engineering Product Portfolio Table 124. Bristol-Myers Squibb Recent Development Table 125. Amgen Company Information Table 126. Amgen Business Overview Table 127. Amgen Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Amgen Drugs based on Genetic Engineering Product Portfolio Table 129. Amgen Recent Development Table 130. AbbVie Company Information Table 131. AbbVie Business Overview Table 132. AbbVie Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. AbbVie Drugs based on Genetic Engineering Product Portfolio Table 134. AbbVie Recent Development Table 135. Swedish Orphan Biovitrum Company Information Table 136. Swedish Orphan Biovitrum Business Overview Table 137. Swedish Orphan Biovitrum Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Swedish Orphan Biovitrum Drugs based on Genetic Engineering Product Portfolio Table 139. Swedish Orphan Biovitrum Recent Development Table 140. Organon Pharma Company Information Table 141. Organon Pharma Business Overview Table 142. Organon Pharma Drugs based on Genetic Engineering Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. Organon Pharma Drugs based on Genetic Engineering Product Portfolio Table 144. Organon Pharma Recent Development Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Drugs based on Genetic Engineering Product Image Figure 2. Global Drugs based on Genetic Engineering Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs based on Genetic Engineering Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs based on Genetic Engineering Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Recombinant Growth Factor Image Figure 8. Recombinant Coagulation Factor Image Figure 9. Recombinant Hormone Image Figure 10. Recombinant Interferon Image Figure 11. Recombinant Interleukin Image Figure 12. Fusion Protein Image Figure 13. Other Image Figure 14. Global Drugs based on Genetic Engineering Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Drugs based on Genetic Engineering Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs based on Genetic Engineering Sales Value Share by Type (2021-2032) Figure 17. Autoimmune Diseases Image Figure 18. Cancers Image Figure 19. Metabolic Disorders Image Figure 20. Infectious Diseases Image Figure 21. Global Drugs based on Genetic Engineering Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Drugs based on Genetic Engineering Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Drugs based on Genetic Engineering Sales Value Share by Application (2021-2032) Figure 24. Global Drugs based on Genetic Engineering Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Drugs based on Genetic Engineering Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Drugs based on Genetic Engineering Sales Value (2021-2032) & (US$ Million) Figure 27. North America Drugs based on Genetic Engineering Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Drugs based on Genetic Engineering Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Drugs based on Genetic Engineering Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Drugs based on Genetic Engineering Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Drugs based on Genetic Engineering Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Drugs based on Genetic Engineering Sales Value (2021-2032) & (US$ Million) Figure 33. South America Drugs based on Genetic Engineering Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Drugs based on Genetic Engineering Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Drugs based on Genetic Engineering Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Growth Factor
  • Recombinant Coagulation Factor
  • Recombinant Hormone
  • Recombinant Interferon
  • Recombinant Interleukin
  • Fusion Protein
  • Other
Applications
  • Autoimmune Diseases
  • Cancers
  • Metabolic Disorders
  • Infectious Diseases
Companies covered
  • GenSci
  • Takeda
  • CSPC
  • 3SBIO
  • Sandoz
  • Sanofi
  • Johnson & Johnson
  • Novo Nordisk
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Bayer
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • Swedish Orphan Biovitrum
  • Organon Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs based on Genetic Engineering Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs based on Genetic Engineering Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs based on Genetic Engineering Market Dynamics
  1. 2.1 Drugs based on Genetic Engineering Industry Trends
  2. 2.2 Drugs based on Genetic Engineering Industry Drivers
  3. 2.3 Drugs based on Genetic Engineering Industry Opportunities and Challenges
  4. 2.4 Drugs based on Genetic Engineering Industry Restraints
3 Drugs based on Genetic Engineering Market by Company
  1. 3.1 Global Drugs based on Genetic Engineering Company Revenue Ranking in 2025
  2. 3.2 Global Drugs based on Genetic Engineering Revenue by Company (2021-2026)
  3. 3.3 Global Drugs based on Genetic Engineering Company Ranking (2024-2026)
  4. 3.4 Global Drugs based on Genetic Engineering Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs based on Genetic Engineering Company Product Type and Application
  6. 3.6 Global Drugs based on Genetic Engineering Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs based on Genetic Engineering Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs based on Genetic Engineering Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs based on Genetic Engineering Market by Type
  1. 4.1 Drugs based on Genetic Engineering Type Introduction
  2. 4.1.1 Recombinant Growth Factor
  3. 4.1.2 Recombinant Coagulation Factor
  4. 4.1.3 Recombinant Hormone
  5. 4.1.4 Recombinant Interferon
  6. 4.1.5 Recombinant Interleukin
  7. 4.1.6 Fusion Protein
  8. 4.1.7 Other
  9. 4.2 Global Drugs based on Genetic Engineering Sales Value by Type
  10. 4.2.1 Global Drugs based on Genetic Engineering Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Drugs based on Genetic Engineering Sales Value by Type (2021-2032)
  12. 4.2.3 Global Drugs based on Genetic Engineering Sales Value Share by Type (2021-2032)
5 Drugs based on Genetic Engineering Market by Application
  1. 5.1 Drugs based on Genetic Engineering Application Introduction
  2. 5.1.1 Autoimmune Diseases
  3. 5.1.2 Cancers
  4. 5.1.3 Metabolic Disorders
  5. 5.1.4 Infectious Diseases
  6. 5.2 Global Drugs based on Genetic Engineering Sales Value by Application
  7. 5.2.1 Global Drugs based on Genetic Engineering Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drugs based on Genetic Engineering Sales Value by Application (2021-2032)
  9. 5.2.3 Global Drugs based on Genetic Engineering Sales Value Share by Application (2021-2032)
6 Drugs based on Genetic Engineering Regional Value Analysis
  1. 6.1 Global Drugs based on Genetic Engineering Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs based on Genetic Engineering Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs based on Genetic Engineering Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs based on Genetic Engineering Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs based on Genetic Engineering Sales Value (2021-2032)
  7. 6.3.2 North America Drugs based on Genetic Engineering Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs based on Genetic Engineering Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs based on Genetic Engineering Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs based on Genetic Engineering Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs based on Genetic Engineering Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs based on Genetic Engineering Sales Value (2021-2032)
  16. 6.6.2 South America Drugs based on Genetic Engineering Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs based on Genetic Engineering Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs based on Genetic Engineering Sales Value Share by Country, 2025 VS 2032
7 Drugs based on Genetic Engineering Country-level Value Analysis
  1. 7.1 Global Drugs based on Genetic Engineering Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs based on Genetic Engineering Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs based on Genetic Engineering Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs based on Genetic Engineering Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs based on Genetic Engineering Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs based on Genetic Engineering Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs based on Genetic Engineering Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GenSci
  2. 8.1.1 GenSci Company Information
  3. 8.1.2 GenSci Business Overview
  4. 8.1.3 GenSci Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GenSci Drugs based on Genetic Engineering Product Portfolio
  6. 8.1.5 GenSci Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Drugs based on Genetic Engineering Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 CSPC
  14. 8.3.1 CSPC Company Information
  15. 8.3.2 CSPC Business Overview
  16. 8.3.3 CSPC Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Drugs based on Genetic Engineering Product Portfolio
  18. 8.3.5 CSPC Recent Developments
  19. 8.4 3SBIO
  20. 8.4.1 3SBIO Company Information
  21. 8.4.2 3SBIO Business Overview
  22. 8.4.3 3SBIO Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  23. 8.4.4 3SBIO Drugs based on Genetic Engineering Product Portfolio
  24. 8.4.5 3SBIO Recent Developments
  25. 8.5 Sandoz
  26. 8.5.1 Sandoz Company Information
  27. 8.5.2 Sandoz Business Overview
  28. 8.5.3 Sandoz Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sandoz Drugs based on Genetic Engineering Product Portfolio
  30. 8.5.5 Sandoz Recent Developments
  31. 8.6 Sanofi
  32. 8.6.1 Sanofi Company Information
  33. 8.6.2 Sanofi Business Overview
  34. 8.6.3 Sanofi Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Drugs based on Genetic Engineering Product Portfolio
  36. 8.6.5 Sanofi Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Drugs based on Genetic Engineering Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Drugs based on Genetic Engineering Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck Drugs based on Genetic Engineering Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Roche Drugs based on Genetic Engineering Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Eli Lilly
  62. 8.11.1 Eli Lilly Company Information
  63. 8.11.2 Eli Lilly Business Overview
  64. 8.11.3 Eli Lilly Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly Drugs based on Genetic Engineering Product Portfolio
  66. 8.11.5 Eli Lilly Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Drugs based on Genetic Engineering Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 GlaxoSmithKline
  74. 8.13.1 GlaxoSmithKline Company Information
  75. 8.13.2 GlaxoSmithKline Business Overview
  76. 8.13.3 GlaxoSmithKline Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  77. 8.13.4 GlaxoSmithKline Drugs based on Genetic Engineering Product Portfolio
  78. 8.13.5 GlaxoSmithKline Recent Developments
  79. 8.14 Biogen
  80. 8.14.1 Biogen Company Information
  81. 8.14.2 Biogen Business Overview
  82. 8.14.3 Biogen Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biogen Drugs based on Genetic Engineering Product Portfolio
  84. 8.14.5 Biogen Recent Developments
  85. 8.15 Bayer
  86. 8.15.1 Bayer Company Information
  87. 8.15.2 Bayer Business Overview
  88. 8.15.3 Bayer Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bayer Drugs based on Genetic Engineering Product Portfolio
  90. 8.15.5 Bayer Recent Developments
  91. 8.16 Bristol-Myers Squibb
  92. 8.16.1 Bristol-Myers Squibb Company Information
  93. 8.16.2 Bristol-Myers Squibb Business Overview
  94. 8.16.3 Bristol-Myers Squibb Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bristol-Myers Squibb Drugs based on Genetic Engineering Product Portfolio
  96. 8.16.5 Bristol-Myers Squibb Recent Developments
  97. 8.17 Amgen
  98. 8.17.1 Amgen Company Information
  99. 8.17.2 Amgen Business Overview
  100. 8.17.3 Amgen Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Amgen Drugs based on Genetic Engineering Product Portfolio
  102. 8.17.5 Amgen Recent Developments
  103. 8.18 AbbVie
  104. 8.18.1 AbbVie Company Information
  105. 8.18.2 AbbVie Business Overview
  106. 8.18.3 AbbVie Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  107. 8.18.4 AbbVie Drugs based on Genetic Engineering Product Portfolio
  108. 8.18.5 AbbVie Recent Developments
  109. 8.19 Swedish Orphan Biovitrum
  110. 8.19.1 Swedish Orphan Biovitrum Company Information
  111. 8.19.2 Swedish Orphan Biovitrum Business Overview
  112. 8.19.3 Swedish Orphan Biovitrum Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Swedish Orphan Biovitrum Drugs based on Genetic Engineering Product Portfolio
  114. 8.19.5 Swedish Orphan Biovitrum Recent Developments
  115. 8.20 Organon Pharma
  116. 8.20.1 Organon Pharma Company Information
  117. 8.20.2 Organon Pharma Business Overview
  118. 8.20.3 Organon Pharma Drugs based on Genetic Engineering Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Organon Pharma Drugs based on Genetic Engineering Product Portfolio
  120. 8.20.5 Organon Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst